Northern Trust
INTS icon

Northern Trust’s Intensity Therapeutics INTS Stock Holding History

Northern Trust’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,022
Closed -$31K – 4472
2025
Q4 		$31K Buy
3,022
+2,461
+439% +$25K ﹤0.01% 4347
2025
Q3 		$3.4K Hold
561
– – ﹤0.01% 4420
2025
Q2 		$4.3K Hold
561
– – ﹤0.01% 4393
2025
Q1 		$27.6K Buy
+561
New +$31.2K ﹤0.01% 4302

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust's INTS Position: Q1 2026 in Review

Northern Trust sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 3,022 shares — an estimated $31K sold.

Northern Trust first reported a position in INTS in Q1 2025 and held it in 4 quarters. The position peaked at $31K in Q4 2025. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Northern Trust reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 3,022 Intensity Therapeutics shares in Q1 2026, an estimated $31K.
  • Northern Trust first reported a position in Intensity Therapeutics in Q1 2025 and held it in 4 quarters.
  • Northern Trust's Intensity Therapeutics position peaked at $31K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.